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ABSTRACT
 
Objectives:
 
A  clinical  trial,  “Belgian  Improvement  Study
on Oral Anticoagulation Therapy (BISOAT),” signiﬁcantly
improved the quality after implementing four different qual-
ity-improving interventions in four randomly divided groups
of general practitioners (GPs). The quality-improving inter-
ventions consisted of multifaceted education with or without
feedback reports on their performance, international normal-
ized ratio (INR) testing by the GP with a CoaguChek device
or computer-assisted advice for adapting oral anticoagula-
tion therapy. The quality improvement in INR control versus
baseline was similar in the four groups. The aim of the cur-
rent study was to calculate the cost-effectiveness and inﬂu-
encing factors of the four quality-improving interventions
compared with usual care.
 
Methods:
 
Activity-based costing techniques with question-
naires were used to determine the global costs per patient per
month in the different intervention groups. Effectiveness data
were obtained from the BISOAT study. Cost-effectiveness
was expressed as cost per additional day within a 0.5 range
from INR target.
 
Results:
 
The one-time cost of multifaceted education was
 
€
 
49,997 for the whole study. Monthly continuous costs per
intervention ranged between 
 
€
 
37 and 
 
€
 
54 per patient. Using
the CoaguChek in combination with the multifaceted educa-
tion was associated with net savings and quality improve-
ment, hence dominated usual care. Sensitivity analyses
showed improved cost-effectiveness with extended duration
and with increased program size.
 
Conclusion:
 
Implementation of the combination multifac-
eted education with the use of the CoaguChek is a cost-
effective new organizational model of oral anticoagulation
management in general practice.
 
Keywords:
 
 cost-effectiveness, economics, general practi-
tioner, oral anticoagulation management, quality
improvement.
 
Introduction
 
Two retrospective studies demonstrated that the qual-
ity of oral anticoagulation management is suboptimal
in Belgium [1,2]. The current management of oral anti-
coagulation in Belgium is organized as follows: A
venous blood sample is taken by the general practi-
tioner (GP) at the patient’s home or in the ofﬁce. The
blood analysis is performed by an external laboratory.
After obtaining the international normalized ratio
(INR), the patient gets information from the GP
regarding the dosage for the following days or weeks.
A clinical trial within 66 GP practices, “Belgian
Improvement Study on Oral Anticoagulation Therapy
(BISOAT),” signiﬁcantly improved the quality com-
pared with baseline after the randomized implemen-
tation of four quality-improving interventions [3].
Nevertheless, no statistically signiﬁcant difference in
quality between the different groups was found. In the
BISOAT study, each group received a multifaceted edu-
cation on oral anticoagulation, namely an interactive
education program, a Web site with guidelines, anti-
coagulation ﬁles combined with patient information
booklets and patient anticoagulation forms. In addi-
tion to this, GPs of group B received written feedback
on their anticoagulation performance every 2 months
[4]. The feedback was a comparison of the GP practice
performance with the mean clinical performance of
group B. In addition to the multifaceted education,
group C determined the INR with a CoaguChek
(Roche Diagnostics GmbH, Mannteim Germany)
device in the doctor’s ofﬁce or at the patient’s home.
The CoaguChek is a portable device that instantly
determines the INR using a capillary blood sample
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[5,6]. Group D received, in addition to the education,
Dawn AC (4S Information Systems, Cumbria, United
Kingdom) computer-assisted advice for adapting the
oral anticoagulation [7]. This computer program
determines the adequate doses of the oral anticoagu-
lant and the date for the next blood test. The GPs were
free to follow the computer advice. Multifaceted edu-
cation and feedback are professional interventions,
whereas the CoaguChek device and computer-assisted
advice are organizational interventions [8].
The latter implies a redistribution of tasks and
responsibilities, leading to a new organizational
model. Current reimbursement constraints have
increased the need for providers to be cost conscious
[9]. Therefore, implementing new professional or
organizational interventions on a large scale implies
the need for an economic analysis. In the current study,
activity-based costing (ABC) was used to detect the
global costs by including the costs associated with all
related activities, for example, blood sampling, trans-
portation of blood samples, testing . . . The cost of
each activity includes both the cost of performing the
activity (unit cost per actor multiplied with labor time)
and the cost of the material required. The aim of this
study was to calculate the cost-effectiveness and its
inﬂuencing factors when implementing the different
quality-improving interventions, in comparison with
usual care. Effectiveness data were obtained from the
BISOAT study.
 
Methods
 
Study Design
 
This study is a cost-effectiveness analysis. The effec-
tiveness data were derived from the clinical results
reported in the BISOAT study. Costs were calculated
by ABC analysis of the BISOAT study using structured
interviews with participating physicians. For each of
the four interventions as well as for usual care (before
baseline), all activities were recorded in ﬂow charts.
For each activity, the required material as well as the
labor time was determined on the basis of structured
interviews with involved persons. Material costs were
calculated on the basis of consumption multiplied by
the unit cost per item. For materials that can be used
for multiple activities, a proportional cost per activity
was applied.
The costs of labor time were calculated by multi-
plying the labor time of each person involved in a cer-
tain activity with their respective cost per unit of
labor time. The structured interviews were based on
the following principles: all steps in which the
respondent was involved were identiﬁed and for each
step the respondent was requested to list the material
required, to estimate the time involved, and to esti-
mate the frequency of performing that step. The
health-care payers are the perspective of the analysis
and no patient costs (e.g., travel time, missed work)
are included in the calculations. The Ethics Commit-
tee of the Catholic University Leuven approved the
BISOAT study. The participating GPs signed an
informed consent.
 
Population
 
The study was performed on the health-care providers
who participated in the BISOAT study [3]. In total 66
GP practices and 834 patients on oral anticoagulation
were included in the latter study. All the persons who
were involved in the organization of the study were
interviewed: the study coordinator, biologist, labora-
tory assistant, and information technology (IT) spe-
cialist. Of the 66 participating GP practices, 16 GPs
randomly divided over four intervention groups were
selected to be interviewed by one interviewer (four GPs
per group). These persons were interviewed 3 months
after the end of the BISOAT study. To avoid bias on
material utilized and time associated with the interven-
tion, the interviewer asked to perform the different
interventions during the interview and measured time
with a chronometer. The reported frequency of per-
forming tasks was controlled with the prospective data
collection of BISOAT trial.
 
Unit Costs
 
Unit costs for material were obtained from the cen-
tral lab, Roche Diagnostics, and 4S Dawn Clinical
Software. The acquisition cost for the INR device at
the central laboratory was 
 
€
 
36,300 with a deprecia-
tion period of 5 years. In addition, the annual cost
for device maintenance and repair is 
 
€
 
3500. The
resulting total cost per year is 
 
€
 
10,760. Based on the
number of INR tests performed in the lab (on aver-
age 4075 per month), the cost per test equals 
 
€
 
0.22.
The unit cost of the CoaguChek device was 
 
€
 
1053
and a depreciation period of 4 years was used. Based
on the frequency of INR testing per GP practice, a
proportional cost of 
 
€
 
2.28 per test was calculated. A
test strip for the device costed 
 
€
 
4.5. The cost of a
Dawn AC computer program (one user and 250
active patients) was 
 
€
 
4310 for the ﬁrst year. In the
second and subsequent years the cost of major
upgrades, would be 
 
€
 
862. The resulting cost per test
is 
 
€
 
0.86 in the ﬁrst year and 
 
€
 
0.17 in subsequent
years. For personnel involved in study organization,
labor-time costs were based on the estimated monthly
total cost to the employer. This led to the following
daily costs: 
 
€
 
159 per day for administrative person-
nel, 
 
€
 
227 for medical study coordinators, 
 
€
 
193 for IT
personnel, 
 
€
 
346 for biologists, 
 
€
 
173 for lab techni-
cians, and 
 
€
 
130 for transport personnel. For study
supervisors, consultancy fees of 
 
€
 
1000 per day were
applied. Unit costs for GP time were based on ofﬁcial
consultation tariffs and labor time per consultation.
Based on the reported proportion of patient visits
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performed at home (30%) and at the ofﬁce (70%)
with a mean duration of 24 min, respectively, 15 min
and the respective tariffs of 
 
€
 
25.3 and 
 
€
 
17.9, the
weighed average cost per minute for the GP was esti-
mated as 
 
€
 
1.15.
 
Overhead Costs of the Laboratory
 
According to the Belgian law, in addition to the cost
per test, a ﬁxed cost per laboratory request per patient
per day is foreseen independent of the number of blood
samples (
 
€
 
20.1). This cost can be considered to repre-
sent the overhead costs associated with organization of
the laboratory (building, maintenance, administration,
administrative personnel, handling waste . . .). A reg-
istration on three consecutive days of all samples in the
laboratory revealed that only 20% of INR tests are
associated with any other laboratory tests at the same
day. For the entire laboratory patient population it
revealed an average of two samples taken per patient
per day. Hence, strictly taken, in 80% of cases the
ﬁxed honorarium can be attributed solely to the INR
test. Nevertheless, given that this ﬁxed fee can be con-
sidered as a compensation for general working costs
and overhead costs, a proportional cost of 
 
€
 
10.05 per
sample was attributed, based on the average sample
number per day in the entire population tested.
 
Deﬁnitions of Costs
 
The one-time costs of the multifaceted education are
incurred  only  at  the  start  of  the  study.  These  costs
are presented at different levels: study, GP-practice or
patient level. These costs contain the following: the
preparation and organizing of the guidelines, of the
educational sessions, of the GP anticoagulation ﬁles, of
the patient information booklets and of the Web site.
The one-time costs of the implementation of the dif-
ferent interventions are calculated separately because
these are different per intervention group. These costs
contain the dispensing and explaining of the informa-
tion booklets and ﬁlling in the anticoagulation ﬁles for
all the intervention groups at the patient level. In group
B and D supplementary costs are generated at the
study level. In group B, the creating of a patient ﬁle
for the feedback (labor time of the IT specialist) is
counted. The set-up, collecting, and introducing
patient information in the Dawn AC computer pro-
gram is counted in group D.
Continuous costs are costs incurred during the con-
duct of the study. On the level of the GPs, the costs for
the blood sampling are taken into account for groups
A, B, and D (Table 1). For group C costs at the GP level
are related to the usage of the CoaguChek device and
test strips. On the level of the laboratory the transport
of the blood samples, the INR analysis, and overhead
costs are counted. In addition, the costs for preparing
the data ﬁles for the feedback reports every 2 months in
group B are registered on this level. For group C, the
only cost incurred at laboratory level is for quality con-
trol of the CoaguChek device by the laboratory per-
sonnel every 3 months. For group D a supplementary
cost due to the Dawn AC computer program is taken
into account on this level. These continuous costs are
calculated per test. Total continuous costs per patient
per month in the different intervention groups were cal-
culated by multiplying the cost per test with the mean
number of tests per month per intervention group of
the BISOAT study. The mean number of tests per
month during the study was 2.6 at baseline (usual care)
and 2.2, 2.2, 2.6, and 1.9 for intervention groups A, B,
C, and D, respectively (non signiﬁcant) [1,3].
The research costs (preparing study protocol, data
analysis, and manuscript) were not taken into account.
 
Analyses
 
The incremental cost-effectiveness ratio (ICER) per GP
practice per 6 months versus usual care was calculated
for each intervention (Table 2). The ICER represents
the additional cost required to provide one unit of
additional effect. The ICER was calculated using the
following formula [10]:
The cumulative cost over 6 months per GP practice is
calculated by summing the one-time costs of the mul-
tifaceted education with the one-time costs of the
implementation  of  the  different  interventions  and
the continuous costs per GP practice (Table 2). The
number of days were derived from the BISOAT study
[3]. Hence, the outcome of this ratio is expressed as the
cost per day within range (DWR), meaning the addi-
tional cost per supplementary day within the 0.5 range
from target.
 
Sensitivity Analyses
 
To examine the inﬂuence of uncertainties in the varia-
bles on the estimated results, one-way sensitivity anal-
yses were performed (Table 3) [11]. Using this type of
analysis the impact of each variable in the study will be
examined by varying it across a plausible range of val-
ues while holding all other variables in the analysis
constant at their “best estimate” or baseline value. The
inﬂuences of uncertainties in the following variables
will be examined: effectiveness parameter (using the
95% conﬁdence interval [CI]); INR testing rate (2.6
instead of the mean testing rate of the intervention
group); overhead costs of the laboratory (
 
€
 
8 and 
 
€
 
5
instead of 
 
€
 
10.05); duration of the study (1 year
instead of 6 months); number of GP practices (150
practices instead of 66 practices) and number of
cumulative cost per 6 months in the intervention
group cumulative cost per 6 months with usual care
number of days within 0.5 range from target
number of days within 0.5 range from target
intervention
usual care
-
( )
- ( )
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patients on oral anticoagulation per GP practice (20
patients instead of 12.6 patients). All analyses were
processed with Excel XP Professional (Microsoft Cor-
poration, Redmond, WA).
 
Results
 
One-Time Costs of the Multifaceted Education (Table 2)
 
The total cost of organizing the multifaceted education
was 
 
€
 
49,997. Costs at study level (setting up guide-
lines, setting up a Web site, preparing the content of
documents for GPs and patients) accounted for a total
amount of 
 
€
 
33,695. These costs are not dependent on
the size or duration of the program. Sixty-six GP prac-
tices were included in the study so this represented a
cost of 
 
€
 
511 per GP practice. Costs at the GP-practice
level (holding educational sessions and producing GP
anticoagulation ﬁles) amounted to 
 
€
 
13,325. An addi-
tional fee for the presence at the educational sessions
of 
 
€
 
208 per GP practice was foreseen. This led to a
total cost of 
 
€
 
410 per GP practice. Per patient, a cost of
 
€
 
3.6 was incurred for producing and handling patient
documentation booklets. With a mean number of 12.6
patients on oral anticoagulation per GP practice, this
counted for 
 
€
 
45 per GP practice.
 
One-Time Costs of the Implementation of the Different 
Interventions (Table 2)
 
The average labor time of the GP for dispensing and
explaining of the information booklets and ﬁlling in the
anticoagulation ﬁles at the start of the study was
reported as 16.5 min, hence accounting for 
 
€
 
19 per
patient or 
 
€
 
241 per GP practice. Supplementary to the
latter costs, in group D 
 
€
 
4.78 per patient was calculated
for introducing patient information in the Dawn AC
program by the biologist. As a result the total cost per
GP practice amounts to 
 
€
 
301. In group B a one-time
 
Table 1
 
Continuous costs (
 
€
 
) per intervention group
 
Person Cost type
Usual 
care A B C D
Cost per test-GP level
Blood sampling/INR testing GP Material 0.32 0.32 0.32 7.30 0.32
INR testing GP Labor 0.00 0.00 0.00 2.57 0.00
Handling samples GP Labor 2.30 2.30 2.30 0.00 2.30
Handling INR results GP Labor 3.16 3.16 3.16 0.80 3.16
Patients questions GP Labor 0.89 0.89 0.89 0.89 0.89
Handling stock GP Labor 1.32 1.32 1.32 0.10 1.32
Control/calibration GP Labor 0.00 0.00 0.00 0.10 0.00
Discuss information booklets* GP Labor 0.00 0.06 0.06 0.06 0.06
Filling in AC ﬁle GP Labor 0.00 2.26 2.26 2.26 2.26
Review quality reports* GP Labor 0.00 0.00 0.07 0.00 0.00
Computer-generated advice GP Labor 0.00 0.00 0.00 0.00 1.15
Cost per test-laboratory level
Transportation of samples Transport Labor 
 
+
 
 
transport
0.99 0.99 0.99 0.00 0.99
Sample receipt 
 
+
 
 preparation LabTec Labor 0.56 0.56 0.56 0.00 0.56
Material for blood testing Material 0.56 0.56 0.56 0.00 0.56
Performing the test LabTec Labor 0.06 0.06 0.06 0.00 0.06
Handling test results Clin Biol Labor 0.09 0.09 0.09 0.00 0.09
Handling test results LabTec Labor 0.24 0.24 0.24 0.00 0.24
Repeated testing LabTec Labor 0.15 0.15 0.15 0.00 0.15
Overhead costs Overhead 10.05 10.05 10.05 0.00 10.05
Transport (control 
 
+
 
 calibration) Transport Labor 
 
+
 
transport
0.00 0.00 0.00 0.02 0.00
Device control and calibration LabTec Labor 0.00 0.00 0.00 0.03 0.00
Dawn AC software use
 
†
 
Cost 0.00 0.00 0.00 0.00 0.86
Data entry INRs in Dawn Clin Biol Labor 0.00 0.00 0.00 0.00 1.08
Print out advices Clin Biol Labor 0.00 0.00 0.00 0.00 0.18
Fax advices Clin Biol Labor 0.00 0.00 0.00 0.00 0.18
Material Material 0.00 0.00 0.00 0.00 0.25
Advice communications Clin Biol Labor 0.00 0.00 0.00 0.00 1.08
Weekly queries from database IT Labor 0.00 0.00 0.00 0.00 0.17
Monthly maintenance software IT Labor 0.00 0.00 0.00 0.00 0.04
Extract data for report IT Labor 0.00 0.00 0.02 0.00 0.00
Analysis for reports StCo Labor 0.00 0.00 0.19 0.00 0.00
Produce reports (material) Material 0.00 0.00 0.04 0.00 0.00
Administrative cost Se Labor 0.00 0.00 0.13 0.00 0.00
Total cost per test 20.69 23.01 23.46 14.13 28.00
Total cost per patient per month
 
‡
 
53.79 50.62 51.61 36.74 53.20
 
*Costs per test are calculated based on the labor cost per month, and the frequency of INR testing.
 
†
 
Fixed cost of 
 
€
 
4310 per 250 patients per year Costs per test are based on the mean number of tests per day and the number of days per year. Note that in subsequent years
this cost goes down to 862 per year, hence 0.17 per test. Hence, the total cost per test decreases to 
 
€
 
31.12 after 1 year.
 
‡
 
Applying the monthly testing rates observed in the BISOAT study.
AC, anticoagulation; BISOAT, Belgian Improvement Study on Oral Anticoagulation Therapy; GP, general practitioner; INR, international normalized ratio.
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cost of 
 
€
 
65 at study level was generated and accounting
for a supplementary cost of 
 
€
 
1 per GP practice. In group
D 
 
€
 
1423 were generated as a result of labor time of the
IT specialist and the study team for setting up, collect-
ing, and introducing patient information in the Dawn
AC computer program. This represented an additional
cost of 
 
€
 
22 per GP practice in this study group.
 
Continuous Costs of Usual Anticoagulation Management 
(Table 1)
 
The total cost of usual care results from adding up the
costs at the GP level and at the laboratory level. Taking
into account labor time, material, and overhead, the
total cost of INR testing was calculated as 
 
€
 
20.69 per
 
Table 2
 
Cost-effectiveness over 6 months per GP practice
 
Usual care A B C D
Unique costs (
 
€
 
) of multifaceted education per level and counted per GP practice
Study level 0 511 511 511 511
GP level 0 410 410 410 410
Patient level 0 45 45 45 45
Costs (
 
€
 
) due to different interventions
Study level 0 0 1 0 22
Patient level 0 241 241 241 301
Continuous 4080 3839 3914 2786 4035
(6 months)*
Cumulative costs 4080 5046 5122 3993 5323
Incremental cost vs. usual care
 
†
 
966 1042
 
−
 
87 1243
% improvement
 
‡
 
Mean (%) 8 9 11 11
95% CI 2.0 4.0 6.0 5.5
95% CI 13.5 13.5 16.5 16.5
Absolute improvement (6 months)
 
§
 
Mean (N days/GP) 185 208 254 254
95% CI 46 92 138 127
95% CI 311 311 381 381
Incremental cost-effectiveness vs. usual care 5.23 5.02 Dominant
 
||
 
4.90
 
*Continuous cost per patient per month multiplied by 12.64 (mean number of patients per GP practice) and multiplied by 6 (6 months).
 
†
 
Incremental cost: total cost usual care—total cost per intervention group.
 
‡
 
% improvement of days within 0.5 range from target per intervention group compared with usual care.
 
§
 
182.5 days (days in 6 months)  * 0.08 (percentage improvement) multiplied with 12.64 (mean number of patients per GP practice) 
 
=
 
 absolute improvement.
 
||
 
Strategy C is less costly and more effective than usual care. Therefore, it is dominant over usual care.
CI, conﬁdence interval; GP, general practitioner.
 
Table 3
 
One-way sensitivity analysis on the ICERs as expressed in 
 
€
 
 per supplementary day within range compared with usual care
 
Variables Usual care A B C D
Absolute improvement (days within range)
Minimum value 95% CI ICER vs. UC 20.93 11.29 Dominant* 9.80
Maximum value 95% CI ICER vs. UC 3.10 3.35 Dominant* 3.27
Testing rate/patient/month (base case 
 
=
 
 study data)
2.6 tests/patient/month Cost 4080 5744 5833 3993 6809
ICER vs. UC 9.02 8.45 Dominant* 10.76
Overhead costs central lab (base case 
 
=
 
 10.05)
 
€
 
8.0 per sample Total cost 3587 4628 4704 3993 4963
ICER vs. UC 5.64 5.38 1.60 5.42
 
€
 
5.0 per sample Total cost 2995 4128 4204 3993 4530
ICER vs. UC 6.14 5.82 3.93 6.05
Extend duration to 1 year
 
†
 
Total cost 8159 8885 9036 6779 9358
Total effectiveness 369 415 507 507
ICER vs. UC 1.96 2.11 Dominant* 2.36
Extend target to 150 GPs
Total cost 4080 4760 4835 3707 5025
Total effectiveness 185 208 254 254
ICER vs. UC 3.68 3.64 Dominant* 3.73
Average of 20 patients per GP
Total cost 6455 7447 7567 5781 7874
Total effectiveness 292 329 402 402
ICER vs. UC 3.40 3.38 Dominant* 3.53
 
*Strategy C is less costly and more effective than usual care. Therefore, it is dominant over usual care.
 
†
 
With the assumption that effectiveness remains throughout the year.
CI, conﬁdence interval; GP, general practitioner; ICER, incremental cost-effectiveness ratio; UC, usual care.
 Claes et al.374
test. With a mean of 2.6 tests per patients per month,
this represents a cost of €53.79 per patient per month,
hence an average of €4080 per 6 months per GP
practice.
Continuous Costs Due to the Different Interventions 
(Table 1)
The monthly cost per patient was €50.62 in group A.
This is lower than for usual care as a result of a lower
testing frequency in this group. In group B, the feed-
back reports every 2 months incurred an extra cost,
leading to a total of €23.46 per test or €51.61 per
patient per month. In group C, the average duration of
the patient visit was slightly increased because of the
testing  of  the  INR  on  the  spot.  On  the  other  hand,
no blood sample handling was required in this group
and results were immediately available for interpreta-
tion and treatment adaptation. Additional activities
required for this group consisted of stock management
for test strips and performing calibration of the Coagu-
Chek device every 3 months. As a result of the impor-
tant savings in this group at the laboratory level, the
cost per test was reduced to €14.13. This accounts for
€36.74 per patient per month. In group D multifaceted
education and computer-assisted anticoagulation mon-
itoring were foreseen. The costs associated with this
intervention include the cost of computer software,
entering daily the required patient information in the
computer and generating and communicating the
advice. At the GP level, costs are incurred by the labor
time involved in reviewing the recommendations, as
well as by potential actions in response to the compu-
ter advice. The total cost estimate is €28.00 per test
and €53.20 per patient per month.
Cost-Effectiveness (Table 2)
In the base case ICER calculations, intervention C was
shown dominant over usual care because of cost sav-
ings combined with quality improvement. The ICER
for intervention A was €5.2 per DWR, for intervention
B €5 per DWR, and for intervention D €4.9 per DWR.
Interventions A and B are less effective but also slightly
less costly compared with D resulting in comparable
cost-effectiveness ratios.
One-Way Sensitivity Analysis (Table 3)
The impact of effectiveness was tested by applying
conﬁdence intervals for the mean improvement. The
cost-effectiveness ratio for intervention A is shown to
be unstable because of the large conﬁdence interval for
improvement. Among the other strategies, the cost-
effectiveness variations are similar and less wide. In
one-way sensitivity analysis the same testing frequency
was applied for all intervention groups for the calcu-
lation of the continuous costs. These results show that
this parameter signiﬁcantly inﬂuences the relative posi-
tion of the different strategies in terms of cost-
effectiveness. Indeed, in the study, group D showed
lower testing frequency than the other groups that
favorably inﬂuenced cost-effectiveness results for this
intervention. The impact of the overhead cost per INR
measurement for the central laboratory was thirdly
tested. If the amount for overhead costs is varied, the
relative position of intervention C within the group
changes. This intervention is highly sensitive to the
overhead cost, which is an important source of savings
from eliminating central lab testing. At an overhead
cost of €8 instead of €10.05, the dominance of inter-
vention C versus usual care is lost. Nevertheless,
within the interventions, it remains the most favorable
option in terms of ICER versus usual care beyond a
50% decrease in overhead costs, up to the level of €2.
Prolonging program duration, assuming sustained
effectiveness, up to 1 year improves the cost-effective-
ness ratio. Cost-effectiveness results were also shown
to improve with assuming larger scale implementation
of each strategy up to 150 GP practices or assuming a
mean number of 20 patients per practice on oral anti-
coagulation instead of 12.6. The latter improvements
in ICERs are the result of reduced one-time costs.
Discussion
The present study evaluates costs and cost-effective-
ness of implementing four quality-improving interven-
tions versus usual care in general practice. The subject
of the study is the oral anticoagulation management
within the GP practice. ABC techniques with question-
naires were used to detect the global costs per patient
per month in the different intervention groups. Being
part of the BISOAT study, the effectiveness data
expressed as the number of days within 0.5 target
range were obtained from this clustered randomized
clinical trial [3]. The interventions signiﬁcantly
improved the quality without, however, a signiﬁcant
difference between the randomized GP practices. Costs
could be distinguished as one-time costs and continu-
ous costs. Continuous costs differed among the differ-
ent interventions in favor for group C. In this group
multifaceted education and the use of a CoaguChek
device by the GPs were implemented. In the latter new
organizational model the GP analyses the INR on cap-
illary blood in usual care the INR analysis is performed
on a venous blood sample in the clinical laboratory.
This implies a reduced continuous cost for intervention
C due to the elimination of venous blood sampling and
overhead costs for the laboratory. These results are in
accordance with literature ﬁnding a signiﬁcant cost
saving per test comparing standard ($15.64) versus
capillary ($7.55) prothrombin time method [12]. In
addition to its cost savings, this new model showed to
signiﬁcantly increase the quality of care. A new health-
care intervention is referred to as the dominant strat-
AC ICER Value in Health 375
egy if it is more effective and less expensive then the
alternative strategy considered in the evaluation (usual
care) [13]. The non signiﬁcant difference in effective-
ness between interventions may suggest that the mul-
tifaceted education is the driving factor in quality
improvement.
The methodology of cost calculations based on
interviews rather than actual time and motion meth-
odology could be regarded as a weakness because it
relies on estimates rather than actual measurements.
Strength of this study on the other hand is that both
costs and efﬁcacy data were obtained from the same
population. In both cases the same individual provided
information of usual care and of care during the inter-
ventions.
Doing cost-effectiveness analysis in implementation
studies to change behavior of health professionals is
still new and little literature is published [8,13,14]. It is
expected that, in the era of increasing costs in health
care partly resulting from new costly techniques and
an aging population in the western countries, this sort
of research will become more important in the future.
This sort of studies is important for policymakers who
are responsible for the health-care budget. Therefore,
to estimate incremental cost-effectiveness from the
health-care payers perspective, Mason principles were
used [10].
The driving factor in the conclusions with regard to
the dominance of intervention C is the overhead cost
assigned to the INR test at the laboratory level. In sen-
sitivity analysis it was shown that decreasing the cost
quickly eliminates the dominance of intervention C. Its
position toward interventions A, B, and D, however, is
quite robust. To assess the robustness of conclusions in
this case, it is important to consider the scale at which
the intervention is supposed to be implemented. If only
a small proportion of practices were to convert to
point of care testing with the CoaguChek device, no
change in overhead or organizational structure at the
lab would be possible. In this situation it might be
argued that the overhead costs would not be elimi-
nated by eliminating the small proportion of INR tests.
Considering, however, as in the current analysis, a
comparison between strategies on a large scale, the
overhead cost can be attributed to the test because
eliminating all INR tests would likely lead to organi-
zational changes in the lab. It must be noted here that
this discussion would be quite different taking a
health-care payers perspective in cost calculations
because in such case the entire ﬁxed honorarium of
€20 can be attributed to approximately 80% of INR
tests. Hence, from the payer’s perspective, the cost sav-
ings of this intervention seem more straightforward.
On the other hand, large scale implementation is then
likely to lead to other changes in budgeting, for exam-
ple, budget transfer from current lab tests to reim-
bursement of CoaguChek device and material and
technical acts at the GP level. For policy decision-
making it is important to assess the cost-effectiveness
of interventions at larger scale and/or duration. In our
sensitivity analysis the ICERs of all the different inter-
ventions improved with longer duration, with imple-
mentation on a lager scale of GP practices and
patients. These latter improvements in ICERs are the
result of reduced one-time costs, especially the cost of
multifaceted education. The one-time costs for multi-
faceted education were quite high, namely €965 per
GP practice per 6 months. Verstappen et al. performed
a cost minimization analyses in an implementation
study comparing two quality strategies (feedback, edu-
cation on guidelines, and quality improvement sessions
vs. feedback alone) on the number of test ordering in
general practice [15]. The cost for the full intervention
group was €702 per GP practice per 6 months. The
intervention led to reduced laboratory test ordering by
the GPs. No effectiveness data on the quality of health
care were available in this study. In our study a
decrease in the number of test was found from 2.6 tests
per patient per month to 2.2 tests per patient per
month. This decrease was due to the education where
GPs were educated to test the stable patients only once
a month. In our sensitivity analysis, testing frequency
was found to have an important impact on costs and
cost-effectiveness results.
This study pointed out the importance of multi-
faceted education in general practice. Our elaborated
multifaceted education program could be easily
implemented in real world, only interactive education
sessions have to be arranged. This will generate an
extra cost of €200 per GP per education session, €208
per GP-practice attendance fee and €45 for the patient
education material. Supplementary, implementing this
program in real world needs a good follow-up:
namely follow-up education sessions in the event of
guidelines change and update of the Web site, anti-
coagulation booklets and ﬁles. This follow-up cost
will be counted in the one-time costs for the next
6 months. One of the pitfalls for implementation in
real world is the lack of reimbursement for postgrad-
uate education in Belgium. In conclusion, our study
suggests that the combination of multifaceted educa-
tion and INR testing by the GP using the CoaguChek
device is a cost saving alternative for usual care. Prov-
ing the cost-effectiveness of this new model of care,
the Belgian health-care payers have to consider reim-
bursement for this new model of care.
Source of ﬁnancial support: No ﬁnancial or other relation-
ships that might lead to a conﬂict of interests are involved. 
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